Royalty Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Royalty Pharma Plc
RPRX Stock  USD 40.65  1.00  2.52%   
Royalty Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Royalty Pharma's valuation are provided below:
Gross Profit
2.5 B
Profit Margin
0.3255
Market Capitalization
23.1 B
Enterprise Value Revenue
10.1
Revenue
2.3 B
We have found one hundred twenty available trending fundamental ratios for Royalty Pharma Plc, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Royalty Pharma Plc recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Enterprise Value is likely to drop to about 16.9 B in 2026

Royalty Pharma Total Revenue

2.73 Billion

Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 272.3 M, Total Revenue of 2.7 B or Research Development of 2.2 M, as well as many indicators such as Price To Sales Ratio of 10.18, Dividend Yield of 0.0363 or PTB Ratio of 1.79. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Build AI portfolio with Royalty Stock
Check out the analysis of Royalty Pharma Correlation against competitors.

Royalty Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets22 B21 B11.2 B
Slightly volatile
Other Current Liabilities292.8 M278.8 M134.2 M
Slightly volatile
Total Current Liabilities1.5 B1.4 B467.2 M
Slightly volatile
Total Stockholder Equity8.4 B8 B4.4 B
Slightly volatile
Other Liabilities2.4 M2.2 M2.6 M
Slightly volatile
Accounts Payable16.1 M15.4 M7.1 M
Slightly volatile
Cash564.5 M1.1 B847.1 M
Slightly volatile
Common Stock Shares Outstanding440.6 M683.1 M446.8 M
Slightly volatile
Short Term Investments1 B968.3 M636 M
Slightly volatile
Inventory1.091.1586.6 M
Very volatile
Other Current Assets4.6 M4.8 M257.8 M
Pretty Stable
Total Liabilities9.5 B9.1 B5 B
Slightly volatile
Common Stock118 K124.2 K579.3 M
Very volatile
Property Plant Equipment2.6 K2.7 K45.4 K
Slightly volatile
Intangible Assets18.3 B17.4 B3.8 B
Slightly volatile
Net Tangible Assets3.7 B6.5 B3.1 B
Slightly volatile
Total Current Assets2.4 B2.1 B1.7 B
Slightly volatile
Short and Long Term Debt Total8 B8.8 B7 B
Slightly volatile
Net Debt5.8 B7.7 B5.1 B
Slightly volatile
Non Current Assets Total13 B18.9 B11.1 B
Slightly volatile
Cash And Short Term Investments2 B2 B1.8 B
Pretty Stable
Liabilities And Stockholders Equity16.1 B21 B14 B
Slightly volatile
Non Current Liabilities Total6.8 B7.6 B6.2 B
Slightly volatile
Short Term Debt1.3 B1.1 B865 M
Slightly volatile
Long Term Debt6.9 B7.6 B6.4 B
Slightly volatile
Net Receivables23 M24.3 M121.6 M
Slightly volatile
Common Stock Total Equity91.5 K96.3 K1.9 B
Slightly volatile
Long Term Debt Total6.9 B7 B6.3 B
Slightly volatile
Net Invested Capital13.6 B16.7 B12.1 B
Slightly volatile
Long Term Investments14.6 B18.8 B11.5 B
Slightly volatile
Short and Long Term Debt703.6 M1.1 B567.9 M
Slightly volatile
Capital Stock92.3 K97.2 K1.9 B
Slightly volatile
Net Working Capital469 M493.7 M1.6 B
Slightly volatile
Current Deferred Revenue24.8 M27.9 M30.5 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity3.6 B3.5 B4.7 B
Slightly volatile
Retained Earnings Total Equity2.3 B2.3 B2 B
Slightly volatile
Capital Surpluse3.7 B4.2 B3.2 B
Slightly volatile
Non Current Liabilities Other14.6 M13.9 M4.4 M
Slightly volatile

Royalty Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Research Development2.2 M2.3 M77.7 M
Very volatile
Selling General Administrative285.8 M272.2 M121.2 M
Slightly volatile
Depreciation And Amortization1.5 B1.5 B288.1 M
Slightly volatile
Other Operating Expenses996.6 M1.1 B909.6 M
Pretty Stable
EBITDA1.7 B1.8 B1.3 B
Slightly volatile
Interest Income45.8 M54.4 M28.3 M
Slightly volatile
Non Recurring1.2 B1.4 B1.5 B
Slightly volatile

Royalty Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow971.6 M836.1 M1.3 B
Slightly volatile
Free Cash Flow2.9 B3.2 B2.2 B
Slightly volatile
Begin Period Cash Flow407.8 M429.3 M1.3 B
Slightly volatile
Other Non Cash Items1.8 B1.6 B1.6 B
Pretty Stable
Dividends Paid403.9 M338.8 M584 M
Slightly volatile
Stock Based Compensation2.4 M2.1 M4.3 M
Slightly volatile
Cash And Cash Equivalents Changes145.1 M152.7 M572.2 M
Slightly volatile
Cash Flows Other Operating2.2 B2.4 B2 B
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.185.7811.1906
Slightly volatile
Dividend Yield0.03630.03810.0391
Slightly volatile
PTB Ratio1.791.883.9741
Slightly volatile
Days Sales Outstanding4.755.024.2642
Slightly volatile
Book Value Per Share14.0520.8714.6575
Slightly volatile
Free Cash Flow Yield0.110.220.1229
Slightly volatile
Operating Cash Flow Per Share4.125.594.6417
Slightly volatile
Stock Based Compensation To Revenue0.00150.00120.0021
Slightly volatile
PB Ratio1.791.883.9741
Slightly volatile
EV To Sales13.19.1813.8838
Slightly volatile
Free Cash Flow Per Share4.125.594.6417
Slightly volatile
ROIC0.10.08270.0872
Pretty Stable
Net Income Per Share2.682.212.0042
Slightly volatile
Sales General And Administrative To Revenue0.06360.09410.0741
Slightly volatile
Research And Ddevelopement To Revenue0.0010.0010.0558
Slightly volatile
Cash Per Share3.543.573.8593
Slightly volatile
POCF Ratio8.864.739.1654
Slightly volatile
Interest Coverage4.735.165.1
Slightly volatile
Payout Ratio0.370.390.9371
Pretty Stable
PFCF Ratio8.864.739.1654
Slightly volatile
Income Quality1.881.871.7599
Slightly volatile
ROE0.20.140.1642
Very volatile
EV To Operating Cash Flow11.917.512.3872
Slightly volatile
PE Ratio11.3211.9250.3487
Very volatile
Return On Tangible Assets0.09210.05420.1021
Slightly volatile
EV To Free Cash Flow11.917.512.3872
Slightly volatile
Earnings Yield0.0490.0680.0492
Slightly volatile
Intangibles To Total Assets4.0E-44.0E-40.2284
Slightly volatile
Net Debt To EBITDA3.473.864.4402
Very volatile
Current Ratio1.571.657.2462
Slightly volatile
Receivables Turnover45.075.5834.5064
Slightly volatile
Graham Number19.923.3820.9639
Slightly volatile
Shareholders Equity Per Share10.1514.0211.1515
Slightly volatile
Debt To Equity1.351.261.2561
Slightly volatile
Revenue Per Share3.754.574.0517
Slightly volatile
Interest Debt Per Share12.7315.8214.048
Slightly volatile
Debt To Assets0.530.480.503
Slightly volatile
Enterprise Value Over EBITDA22.0813.3524.56
Slightly volatile
Short Term Coverage Ratios4.763.194.2353
Slightly volatile
Price Earnings Ratio11.3211.9250.3487
Very volatile
Operating Cycle4.755.024.2642
Slightly volatile
Price Book Value Ratio1.791.883.9741
Slightly volatile
Dividend Payout Ratio0.370.390.9371
Pretty Stable
Price To Operating Cash Flows Ratio8.864.739.1654
Slightly volatile
Price To Free Cash Flows Ratio8.864.739.1654
Slightly volatile
Pretax Profit Margin0.740.680.6106
Slightly volatile
Ebt Per Ebit1.131.181.0252
Pretty Stable
Operating Profit Margin0.70.660.5966
Pretty Stable
Company Equity Multiplier2.12.362.4878
Slightly volatile
Long Term Debt To Capitalization0.590.560.5468
Pretty Stable
Total Debt To Capitalization0.610.60.5597
Very volatile
Return On Capital Employed0.10.08760.089
Pretty Stable
Debt Equity Ratio1.351.261.2561
Slightly volatile
Ebit Per Revenue0.70.660.5966
Pretty Stable
Quick Ratio1.571.657.2462
Slightly volatile
Dividend Paid And Capex Coverage Ratio4.056.623.8036
Slightly volatile
Net Income Per E B T0.750.740.7156
Slightly volatile
Cash Ratio0.810.853.837
Slightly volatile
Cash Conversion Cycle4.755.024.2642
Slightly volatile
Operating Cash Flow Sales Ratio0.81.10.9478
Slightly volatile
Days Of Sales Outstanding4.755.024.2642
Slightly volatile
Cash Flow Coverage Ratios0.250.330.2676
Slightly volatile
Price To Book Ratio1.791.883.9741
Slightly volatile
Price Cash Flow Ratio8.864.739.1654
Slightly volatile
Enterprise Value Multiple22.0813.3524.56
Slightly volatile
Debt Ratio0.530.480.503
Slightly volatile
Cash Flow To Debt Ratio0.250.330.2676
Slightly volatile
Price Sales Ratio10.185.7811.1906
Slightly volatile
Return On Assets0.08130.05420.0673
Very volatile
Asset Turnover0.150.140.1467
Slightly volatile
Net Profit Margin0.560.440.4613
Pretty Stable
Price Fair Value1.791.883.9741
Slightly volatile
Return On Equity0.20.140.1642
Very volatile

Royalty Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap12.6 B14.2 B15.5 B
Slightly volatile
Enterprise Value16.9 B19.6 B21 B
Slightly volatile

Royalty Fundamental Market Drivers

Forward Price Earnings11.5075
Cash And Short Term Investments1.8 B

Royalty Upcoming Events

21st of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue27.9 M24.8 M
Total Revenue2.6 B2.7 B
Cost Of Revenue842.3 M884.4 M
Sales General And Administrative To Revenue 0.09  0.06 
Revenue Per Share 4.57  3.75 
Ebit Per Revenue 0.66  0.70 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY